Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 2-18 years of age.~* Have a diagnosis of Pompe, as defined by protein assay, DNA sequence of the acid alpha-glucosidase gene and clinical symptoms of the disease.~* Using assisted ventilation at baseline. Mechanical Ventilation is defined as any use of ventilation support, (including but not limited to BiPAP, CPAP), a minimum of 1 hours per day.~* Willing to discontinue aspirin, aspirin-containing products and other drugs that may alter platelet function, 7 days prior to dosing, resuming 24 hours after the dose has been administered.~Exclusion Criteria:~The subject must not:~* Have required acute, as distinguished from long-term, maintenance or chronic suppressive, oral or intravenous antibiotic therapy for a respiratory infection within 15 days prior to baseline screening.~* Have required oral or systemic corticosteroids within the last 15 days prior to baseline screening.~* Have a platelet count less than 75,000/ cu mm.~* Have an INR greater than 1.3.~* Serological evidence of hepatitis B, hepatitis C, or HIV positive.~* Be currently or within the past 30 days participating in any other research protocol involving investigational agents or therapies.~* Have received gene transfer agents within the past 6 months.~* Have history of platelet dysfunction, evidence of abnormal platelet function at screening or history of recent use of drugs that may alter platelet function which the subject is unable/unwilling to discontinue for study agent administration.~* Have any other concurrent condition which, in the opinion of the investigator, would make the subject unsuitable for the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- rAAV1-CMV-GAA administration-cohort 1 (Type: EXPERIMENTAL): rAAV1-CMV-GAA (study agent) Administration: 1.0 x 10e12 vector genomes. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
- rAAV1-CMV-GAA administration-cohort 2 (Type: EXPERIMENTAL): rAAV1-CMV-GAA (study agent) Administration: 5.0 x 10e12 vector genomes Cohort 2 = 6 subjects. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).